Leann Tilley | |
|---|---|
 May 2019 in Heidelberg | |
| Born | |
| Nationality | Australian |
| Alma mater | University of Melbourne, University of Sydney |
| Awards |
|
| Scientific career | |
| Fields | Parasitology, biochemistry |
| Institutions | University of Melbourne |
Leann Tilley is Professor of Biochemistry and Molecular Biology in the Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne.
Leann Tilley was born in Edenhope, Victoria, and attended Marian College in Ararat. [2] Following a BSc (hons) in biochemistry at the University of Melbourne, she obtained her PhD in biochemistry from the University of Sydney. She completed postdoctoral fellowships at Utrecht University in the Netherlands, the College de France in Paris, and the University of Melbourne, before joining La Trobe University. In 2011 she moved to the Department of Biochemistry and Molecular Biology at the University of Melbourne. [3]
Professor Tilley was awarded an Australian Research Council Georgina Sweet Australian Laureate Fellowship (2016-2020) to measure and model malaria parasites. [1] This includes a role as an ambassador for women in science. Tilley's work has been recognised by the award of the title of Redmond Barry Distinguished Professor, University of Melbourne (2016), an Australian Research Council Australian Professorial Fellowship (2011-2015), the Bancroft-Mackerras Medal from the Australian Society for Parasitology [4] and the Beckman Coulter Discovery Award of the Australian Society for Biochemistry and Molecular Biology. [5] Her team was awarded the 2016 Eureka Award for Infectious Diseases Research. She was awarded the Bob Robertson Award of the Australian Society for Biophysics in 2017.
Tilley's research focuses on the use of molecular approaches and imaging techniques to study the malaria parasite and its interactions with its host in an effort to develop novel therapies. Her scientific contributions have been in four main areas: 1) Establishing Imaging Facilities and Technologies. For example, Tilley has pioneered the application of methods such as Super-Resolution Optical Microscopy to studies of the malaria parasite. 2) Antimalarial Drug Action. For example, Tilley investigates the molecular basis of the resistance that is currently emerging to the antimalarial drug, artemisinin, [6] [7] with a view to extending the use of a drug that saves millions of lives, 3) Studying the unusual trafficking path that brings P. falciparum virulence proteins to the host red blood cell surface, [8] [9] and 4) Determining the molecular basis of the amazing shape-changing properties of the sexual stage gametocyte.
She served as Deputy Director (2005-2012) and Director (2013-2014) of the Australian Research Council Centre of Excellence for Coherent X-ray Science (CXS). [10]
Malaria is a mosquito-borne infectious disease that affects humans and other animals. Malaria causes symptoms that typically include fever, tiredness, vomiting, and headaches. In severe cases, it can cause jaundice, seizures, coma, or death. Symptoms usually begin ten to fifteen days after being bitten by an infected mosquito. If not properly treated, people may have recurrences of the disease months later. In those who have recently survived an infection, reinfection usually causes milder symptoms. This partial resistance disappears over months to years if the person has no continuing exposure to malaria.
Antimalarial medications or simply antimalarials are a type of antiparasitic chemical agent, often naturally derived, that can be used to treat or to prevent malaria, in the latter case, most often aiming at two susceptible target groups, young children and pregnant women. As of 2018, modern treatments, including for severe malaria, continued to depend on therapies deriving historically from quinine and artesunate, both parenteral (injectable) drugs, expanding from there into the many classes of available modern drugs. Incidence and distribution of the disease is expected to remain high, globally, for many years to come; moreover, known antimalarial drugs have repeatedly been observed to elicit resistance in the malaria parasite—including for combination therapies featuring artemisinin, a drug of last resort, where resistance has now been observed in Southeast Asia. As such, the needs for new antimalarial agents and new strategies of treatment remain important priorities in tropical medicine. As well, despite very positive outcomes from many modern treatments, serious side effects can impact some individuals taking standard doses.
Plasmodium is a genus of unicellular eukaryotes that are obligate parasites of vertebrates and insects. The life cycles of Plasmodium species involve development in a blood-feeding insect host which then injects parasites into a vertebrate host during a blood meal. Parasites grow within a vertebrate body tissue before entering the bloodstream to infect red blood cells. The ensuing destruction of host red blood cells can result in malaria. During this infection, some parasites are picked up by a blood-feeding insect, continuing the life cycle.
Plasmodium falciparum is a unicellular protozoan parasite of humans, and the deadliest species of Plasmodium that causes malaria in humans. The parasite is transmitted through the bite of a female Anopheles mosquito and causes the disease's most dangerous form, falciparum malaria. It is responsible for around 50% of all malaria cases. P. falciparum is therefore regarded as the deadliest parasite in humans. It is also associated with the development of blood cancer and is classified as a Group 2A (probable) carcinogen.
Artemisinin and its semisynthetic derivatives are a group of drugs used in the treatment of malaria due to Plasmodium falciparum. It was discovered in 1972 by Tu Youyou, who shared the 2015 Nobel Prize in Physiology or Medicine for her discovery. Artemisinin-based combination therapies (ACTs) are now standard treatment worldwide for P. falciparum malaria as well as malaria due to other species of Plasmodium. Artemisinin is extracted from the plant Artemisia annua, sweet wormwood, a herb employed in Chinese traditional medicine. A precursor compound can be produced using a genetically engineered yeast, which is much more efficient than using the plant.
Plasmodium knowlesi is a parasite that causes malaria in humans and other primates. It is found throughout Southeast Asia, and is the most common cause of human malaria in Malaysia. Like other Plasmodium species, P. knowlesi has a life cycle that requires infection of both a mosquito and a warm-blooded host. While the natural warm-blooded hosts of P. knowlesi are likely various Old World monkeys, humans can be infected by P. knowlesi if they are fed upon by infected mosquitoes. P. knowlesi is a eukaryote in the phylum Apicomplexa, genus Plasmodium, and subgenus Plasmodium. It is most closely related to the human parasite Plasmodium vivax as well as other Plasmodium species that infect non-human primates.
An apicoplast is a derived non-photosynthetic plastid found in most Apicomplexa, including Toxoplasma gondii, and Plasmodium falciparum and other Plasmodium spp., but not in others such as Cryptosporidium. It originated from algae through secondary endosymbiosis; there is debate as to whether this was a green or red alga. The apicoplast is surrounded by four membranes within the outermost part of the endomembrane system. The apicoplast hosts important metabolic pathways like fatty acid synthesis, isoprenoid precursor synthesis and parts of the heme biosynthetic pathway.
Dihydroartemisinin is a drug used to treat malaria. Dihydroartemisinin is the active metabolite of all artemisinin compounds and is also available as a drug in itself. It is a semi-synthetic derivative of artemisinin and is widely used as an intermediate in the preparation of other artemisinin-derived antimalarial drugs. It is sold commercially in combination with piperaquine and has been shown to be equivalent to artemether/lumefantrine.
The history of malaria extends from its prehistoric origin as a zoonotic disease in the primates of Africa through to the 21st century. A widespread and potentially lethal human infectious disease, at its peak malaria infested every continent except Antarctica. Its prevention and treatment have been targeted in science and medicine for hundreds of years. Since the discovery of the Plasmodium parasites which cause it, research attention has focused on their biology as well as that of the mosquitoes which transmit the parasites.
PfATP6, also known as PfSERCA or PfATPase6, is a calcium ATPase gene encoded by the malaria parasite Plasmodium falciparum. The protein is thought to be a P-type ATPase involved in calcium ion transport.
Piperaquine is an antiparasitic drug used in combination with dihydroartemisinin to treat malaria. Piperaquine was developed under the Chinese National Malaria Elimination Programme in the 1960s and was adopted throughout China as a replacement for the structurally similar antimalarial drug chloroquine. Due to widespread parasite resistance to piperaquine, the drug fell out of use as a monotherapy, and is instead used as a partner drug for artemisinin combination therapy. Piperaquine kills parasites by disrupting the detoxification of host heme.
Pregnancy-associated malaria (PAM) or placental malaria is a presentation of the common illness that is particularly life-threatening to both mother and developing fetus. PAM is caused primarily by infection with Plasmodium falciparum, the most dangerous of the four species of malaria-causing parasites that infect humans. During pregnancy, a woman faces a much higher risk of contracting malaria and of associated complications. Prevention and treatment of malaria are essential components of prenatal care in areas where the parasite is endemic – tropical and subtropical geographic areas. Placental malaria has also been demonstrated to occur in animal models, including in rodent and non-human primate models.
Russell J. Howard is an Australian-born executive, entrepreneur and scientist. He was a pioneer in the fields of molecular parasitology, especially malaria, and in leading the commercialisation of one of the most important methods used widely today in molecular biology today called “DNA shuffling" or "Molecular breeding", a form of "Directed evolution".
Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1) is a family of proteins present on the membrane surface of red blood cells that are infected by the malarial parasite Plasmodium falciparum. PfEMP1 is synthesized during the parasite's blood stage inside the RBC, during which the clinical symptoms of falciparum malaria are manifested. Acting as both an antigen and adhesion protein, it is thought to play a key role in the high level of virulence associated with P. falciparum. It was discovered in 1984 when it was reported that infected RBCs had unusually large-sized cell membrane proteins, and these proteins had antibody-binding (antigenic) properties. An elusive protein, its chemical structure and molecular properties were revealed only after a decade, in 1995. It is now established that there is not one but a large family of PfEMP1 proteins, genetically regulated (encoded) by a group of about 60 genes called var. Each P. falciparum is able to switch on and off specific var genes to produce a functionally different protein, thereby evading the host's immune system. RBCs carrying PfEMP1 on their surface stick to endothelial cells, which facilitates further binding with uninfected RBCs, ultimately helping the parasite to both spread to other RBCs as well as bringing about the fatal symptoms of P. falciparum malaria.
Yagya Dutta Sharma is an Indian molecular biologist, professor and head of the department of biotechnology at the All India Institute of Medical Sciences, Delhi. An elected fellow of all three major Indian science academies — Indian National Science Academy, Indian Academy of Sciences, and National Academy of Sciences, India — Sharma is known for his research on the molecular biology of malaria. The Council of Scientific and Industrial Research, the apex agency of the Government of India for scientific research, awarded him the Shanti Swarup Bhatnagar Prize for Science and Technology for his contributions to medical sciences in 1994.
Asif Mohmmed is an Indian cell biologist, parasitologist and a professor at the International Centre for Genetic Engineering and Biotechnology (ICGEB), New Delhi. At ICGEB, he leads a research group on Parasite Cell Biology and is one of the key collaborators of the Tewari Lab at the School of Life Science of the University of Nottingham. He is known for his studies on Plasmodium falciparum proteases with regard to cellular Stress and parasite cell-death and protein-trafficking machinery in the pathogen, as well as the development of new anti-malarial drugs. His studies have been documented by way of a number of articles and ResearchGate, an online repository of scientific articles has listed 73 of them. The Department of Biotechnology of the Government of India awarded him the National Bioscience Award for Career Development, one of the highest Indian science awards, for his contributions to biosciences, in 2011.
Alan Frederick Cowman AC, FRS, FAA, CorrFRSE, FAAHMS, FASP, FASM is an internationally acclaimed malaria researcher whose work specialises in researching the malaria-causing parasite, Plasmodium falciparum, and the molecular mechanisms it uses to evade host responses and antimalarial drugs. He is currently Deputy Directory of the Walter and Eliza Hall Institute of Medical Research (WEHI) in Melbourne, and his laboratory continues to work on understanding how Plasmodium falciparum, infects humans and causes disease. He was elected as a Fellow of the Royal Society in 2011 and awarded the Companion of the Order of Australia in 2019 for his "eminent service to the biological sciences, notably to molecular parasitology, to medical research and scientific education, and as a mentor."
Wai-Hong Tham is a Malaysian professor at the University of Melbourne and the Walter and Eliza Hall Institute of Medical Research (WEHI), and joint head of the division of Infectious Disease and Immune Defense. She researches the molecular biology of the malaria parasite Plasmodium vivax.
Sanjeev Krishna,, is a British physician and parasitologist whose research focuses on affordable diagnosis and treatment of diseases such as COVID-19, malaria, Ebola, African trypanosomiasis, leishmaniasis, and colorectal cancer. Krishna is Professor of Medicine and Molecular Parasitology at St George's, University of London and St George's Hospital.
David A. Fidock, is the CS Hamish Young Professor of Microbiology and Immunology and Professor of Medical Sciences at Columbia University Irving Medical Center in Manhattan.
| Authority control: Academics |
|---|
